Clinical Trials Browser

Phase 1/2 × OTHER × NET × Clear all

NCT06607692 2026-04-14

LUPARPED

Phase 1/2 Recruiting

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

NCT05048901 2026-04-09

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Phase 1/2 Enrolling by invitation

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT06455358 2025-05-30

61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT03145857 2025-05-14

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT06456723 2025-05-01

FETONET

Phase 1/2 Completed

56 enrolled 9 charts

Neuroendocrine Tumors

NCT06056362 2025-04-02

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Phase 1/2 Completed

Neuroendocrine Tumors

NCT02736500 2025-01-13

LuX

Phase 1/2 Completed

Neuroendocrine Tumors

NCT02749331 2024-12-03

RADNET

Phase 1/2 Active not recruiting

Neuroendocrine Tumors

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Phase 1/2 Recruiting

Neuroendocrine Tumors

NCT04614766 2024-04-29

SPORE-3

Phase 1/2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06155994 2023-12-05

68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours

Phase 1/2 Completed

Neuroendocrine Tumors

NCT03043664 2023-06-29

PLANET

Phase 1/2 Completed

22 enrolled 12 charts

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT04318561 2021-12-21

PET

Phase 1/2 Completed

Neuroendocrine Tumors

NCT01619865 2021-07-27

GA-68

Phase 1/2 Completed

223 enrolled 11 charts

CNSEndocrineNET

Carcinoid Tumor, Medulloblastoma, Neuroblastoma, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03881306 2020-08-20

DEBOXA for Inoperable NET Liver Metastases

Phase 1/2 Unknown

Neoplasm Metastasis, Neuroendocrine Tumors

NCT02177773 2019-11-12

DOTA-TOC

Phase 1/2 Terminated

300 enrolled 5 charts

CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

NCT02030184 2019-10-17

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Phase 1/2 Withdrawn

EndocrineNETThoracic

Lung Neoplasms, Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT00323076 2019-08-26

[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Phase 1/2 Terminated

EndocrineGenitourinaryNET

Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

Phase 1/2 Unknown

Metatropic dwarfism, Neuroendocrine Tumors

NCT03511768 2018-04-30

A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms

Phase 1/2 Unknown

Neuroendocrine Tumors

NCT02078843 2016-09-07

GaIN

Phase 1/2 Terminated

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT02038738 2014-01-17

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Phase 1/2 Unknown

Apudoma, Carcinoid Tumor, Adenoma, Islet Cell, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01175096 2010-08-04

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Phase 1/2 Unknown

Carcinoid Tumor, Neuroendocrine Tumors